Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.
Send Confirmation Email
NASDAQ:RDHL

RedHill Biopharma (RDHL) Stock Price, News & Analysis

→ This Could be Your “Big Money” AI Moment (From InvestorPlace) (Ad)
Free RDHL Stock Alerts
$0.46
-0.01 (-2.87%)
(As of 05:19 PM ET)
Compare
Today's Range
$0.46
▼
$0.48
50-Day Range
$0.38
▼
$0.55
52-Week Range
$0.26
▼
$3.28
Volume
244,591 shs
Average Volume
948,019 shs
Market Capitalization
$13.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
RDHL stock logo

About RedHill Biopharma Stock (NASDAQ:RDHL)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Stock Price History

RDHL Stock News Headlines

May 20 at 3:26 AM | americanbankingnews.com
RedHill Biopharma (NASDAQ:RDHL) Receives New Coverage from Analysts at StockNews.com
May 12, 2024 | americanbankingnews.com
RedHill Biopharma (NASDAQ:RDHL) Now Covered by Analysts at StockNews.com
May 7, 2024 | finanznachrichten.de
RedHill Biopharma Ltd.: RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
May 6, 2024 | prnewswire.com
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
April 24, 2024 | finance.yahoo.com
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
April 10, 2024 | finance.yahoo.com
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
April 9, 2024 | bizjournals.com
Raleigh pharma weighs divesting commercial operations
April 8, 2024 | finanznachrichten.de
RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
April 8, 2024 | finance.yahoo.com
RedHill Biopharma Ltd. (2RH0.F)
April 8, 2024 | prnewswire.com
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
April 2, 2024 | finance.yahoo.com
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
March 11, 2024 | markets.businessinsider.com
RedHill Biopharma Receives New Patent For H. Pylori Treatment Talicia
March 11, 2024 | finance.yahoo.com
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
March 5, 2024 | finance.yahoo.com
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
February 20, 2024 | finance.yahoo.com
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
February 20, 2024 | prnewswire.com
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
February 16, 2024 | barrons.com
RedHill Biopharma Ltd. ADR
January 26, 2024 | finance.yahoo.com
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
January 25, 2024 | msn.com
RedHill gains after new patent grant for Talicia for H. pylori treatment through 2042
January 25, 2024 | finance.yahoo.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
January 25, 2024 | finance.yahoo.com
RedHill Biopharma Announces $8 Million Registered Direct Offering
January 24, 2024 | benzinga.com
Why Redhill Biopharma Stock Is Moving Higher
December 20, 2023 | msn.com
RedHill's Investigational COVID-19 Drugs Combined With Gilead's Show Effect Against Ebola
December 20, 2023 | markets.businessinsider.com
RedHill Announces Results Of A New U.S. Army-funded In Vivo Ebola Virus Study
December 20, 2023 | msn.com
RedHill shares rally 20% on positive data for two antiviral drugs
See More Headlines

Company Calendar

Last Earnings
11/30/2021
Today
5/20/2024
Next Earnings (Estimated)
6/10/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RDHL
CUSIP
N/A
CIK
1553846
Web
www.redhillbio.com
Phone
972-3541-3131
Fax
972-3541-3144
Employees
53
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.84
Quick Ratio
0.61

Sales & Book Value

Annual Sales
$6.53 million
Price / Sales
2.16
Cash Flow
$1.32 per share
Price / Cash Flow
0.36
Book Value
$0.11 per share
Price / Book
4.31

Miscellaneous

Outstanding Shares
29,700,000
Free Float
27,680,000
Market Cap
$14.07 million
Optionable
No Data
Beta
3.47

Key Executives

  • Mr. Dror Ben-Asher (Age 58)
    Co-Founder, Chairman & CEO
    Comp: $594.61k
  • Mr. Razi Ingber (Age 40)
    Chief Financial Officer
    Comp: $339.82k
  • Mr. Gilead Raday MPhil (Age 49)
    MSc, Chief Operating Officer
    Comp: $365.56k
  • Mr. Adi Frish (Age 54)
    Chief Corporate & Business Development Officer
    Comp: $339.3k
  • Mr. Rick D. Scruggs (Age 64)
    Chief Commercial Officer, President of RedHill Biopharma Inc. & Director
    Comp: $469.8k
  • Ms. Alexandra Okmian
    Senior Business Development & Investor Relations Manager
  • Dr. Reza Fathi Ph.D. (Age 69)
    Senior Vice President of Research & Development
    Comp: $299.29k
  • Mr. Guy Goldberg J.D. (Age 48)
    Chief Business Officer
    Comp: $338.13k
  • Dr. June S. Almenoff FACP (Age 67)
    M.D., Ph.D., Chief Medical Officer
  • Ms. Patricia Anderson B.Sc. RAC
    Senior Vice President of Regulatory Affairs

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed in 2024?

RedHill Biopharma's stock was trading at $1.46 at the start of the year. Since then, RDHL stock has decreased by 67.4% and is now trading at $0.4762.
View the best growth stocks for 2024 here.

When is RedHill Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, June 10th 2024.
View our RDHL earnings forecast.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) posted its quarterly earnings results on Tuesday, November, 30th. The biotechnology company reported ($20.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($19.20) by $0.80. The biotechnology company earned $21.61 million during the quarter, compared to the consensus estimate of $23.41 million. During the same quarter in the prior year, the company posted ($20.00) EPS.

When did RedHill Biopharma's stock split?

RedHill Biopharma's stock reverse split before market open on Thursday, March 23rd 2023. The 1-40 reverse split was announced on Thursday, March 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (0.40%).

How do I buy shares of RedHill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RDHL) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners
"The Biggest Drug Ever" Is Coming
Behind the Markets
Exposed: 10 CENT Crypto to Explode May 20th?
True Market Insiders
**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!
Huge Alerts
Warren Buffett's "mystery stock"
Stansberry Research
This Could be Your “Big Money” AI Moment
InvestorPlace
Digitizing the $11T commodities sector with one tiny stock
Resource Stock Digest
Elon to Transform U.S. Economy?
Porter & Company
Former CIA advisor: Dark side of AI now starting
Paradigm Press